Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
Cybin Inc., a biopharmaceutical company focused on progressing Psychedelics to Therapeutics is pleased to announce that it has received approval from an independent ethics committee in…
Read More...
Read More...